DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Accumulated Expenses of $2.3 million for Q1 2026, up 586.22% year-over-year from $341000.0 in Q1 2025, and down 33.99% quarter-over-quarter from $3.5 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 586.22% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 586.22% YoY), while the FY2025 annual figure was $3.5 million, up 234.43% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $3.5 million in the prior quarter.
- The five-year high for Accumulated Expenses was $3.5 million in Q4 2025, with the low at $161000.0 in Q1 2023.
- The 5-year median for Accumulated Expenses is $1.1 million (2024), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses tumbled 83.35% in 2023, then soared 1027.33% in 2024.
- DiaMedica Therapeutics' Accumulated Expenses stood at $1.4 million in 2022, then plunged by 43.88% to $766000.0 in 2023, then soared by 38.38% to $1.1 million in 2024, then jumped by 234.43% to $3.5 million in 2025, then slumped by 33.99% to $2.3 million in 2026.
- Business Quant data shows DMAC's Accumulated Expenses at $2.3 million in Q1 2026, $3.5 million in Q4 2025, and $920000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.67 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 3.55 Mn |
| Sep 30, 2025 | 920,000.00 |
| Jun 30, 2025 | 2.75 Mn |
| Mar 31, 2025 | 341,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 766,000.00 |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 161,000.00 |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 637,000.00 |
| Jun 30, 2022 | 894,000.00 |
| Mar 31, 2022 | 967,000.00 |
| Dec 31, 2021 | 966,000.00 |
| Sep 30, 2021 | 861,000.00 |